问题 › 我们下一步该投资哪里？ › 医疗服务提供商
当价值导向合同下面板扩大，但尚无每期成本数据显示哪些面板能带来下一美元回报时，资本配置就会出错。 对医疗服务提供商来说，这更难是因为结构性原因：在38,000人的 downside risk 已接受，但缺乏定价所需的每期成本数据。因此，任何可信答案都必须将每期成本和付款人组合放在同一视图中，而这正是大多数内部分析停止的地方，因为两者存在于不同系统中。
当价值导向合同下面板扩大，但尚无每期成本数据显示哪些面板能带来下一美元回报时，资本配置就会出错。 对医疗服务提供商来说，这更难是因为结构性原因：在38,000人的 downside risk 已接受，但缺乏定价所需的每期成本数据。因此，任何可信答案都必须将每期成本和付款人组合放在同一视图中，而这正是大多数内部分析停止的地方，因为两者存在于不同系统中。
大多数提供商按历史和倡导分配：去年增长的面板获得下一次招聘，主张更多归属生命的医疗主任获得增量。这两个步骤都没有检查，在已接受现有38,000人 downside risk 的情况下，增加的面板规模是否改善了每个提供商的贡献。
有帮助的分析按两件事对每个面板排序——增量投资的回报以每期成本衡量，以及该回报在当前付款人组合下保持持久的程度。一个快速降低每期成本但在两年内失去归属的面板，与一个在更长合同中保持每个提供商贡献稳定的面板，是不同的命题，将它们视为可比就是提供商资助错误增长的方式。
输出应该是一个带停止规则的序列，而不是预算拆分。哪个面板先获得下一个提供商，哪个每期成本阈值资助下一个，以及归属生命数据中显示序列错误的观察。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 预算按去年的面板规模加百分比设定，不根据当前每期成本重新计算。
✓ CFO 和医疗主任无法按下一美元的每个提供商贡献生成面板排名列表。
✓ 投资案例用增加的归属生命数量而非价值导向合同下测量的每期成本来辩护。
通常会让情况更糟的做法。 将新的提供商位置平均分配到各个面板以保持内部平衡，这使得每期成本最高的面板资金不足，而38,000人的 risk 仍未定价。
It is for you if you run or finance a healthcare provider and budgets are set by last year plus a percentage. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Sell coordinated care bundles directly to self-insured employers using existing clinic density and ASC capacity.
The leak it closes. Bypasses commercial payer take-rate (estimated 15–20% of premium) and prior-authorization friction, reducing denial leakage on these lives to near zero
The assumption it rests on. At least two of the five largest self-insured employers in the two metros will sign a 3-year direct contract within 18 months — the engine put the probability at 0.7.
| Investment required | $2M over 36 months ($800K Year 1, $700K Year 2, $500K Year 3) |
| Expected return | 6.0–9.0× on $2M investment |
| Revenue, year 1 | $0 incremental (pilot setup and first contract negotiations) |
| Revenue, year 2 | $4–6M incremental (2–3 employer contracts, 4,000–6,000 covered lives) |
| Revenue, year 3 | $12–18M incremental (5 employer contracts, 10,000–15,000 covered lives) |
| Exit criteria | Terminate pilot and redeploy 4 FTEs if fewer than 2 employer contracts signed by Month 18 OR if operating margin on employer channel falls below 6% for two consecutive quarters |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 增长投资组合框架, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
明确定价持久性。衰减的回报需要说明半衰期；一旦每个选项都有半衰期，不同时限的选项就变得可比，而非主观偏好。
通常是最强部分，因为那是边际美元复利的地方。修复最弱部分仅在它是制约最强部分的约束时才值得，否则不值得。
那就根据可逆性决定。当两个选项回报相似时，选择可以停止的那个，因为你获得的信息价值超过估算差异。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית